share_log

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

大自然藥業 | 6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/10/11 04:15

Moomoo AI 已提取核心訊息

Universe Pharmaceuticals announced the appointment of Enrome LLP as its new independent registered public accounting firm effective October 8, 2024, replacing YCM CPA INC. The change was approved by the company's audit committee after careful consideration and evaluation.The company emphasized that the auditor change was not due to any disagreements on accounting principles, financial statement disclosure, or auditing procedures. YCM's audit reports for fiscal years 2022 and 2023 contained no adverse opinions or modifications. The only notable issue was previously reported material weaknesses under Item 15 of the company's annual report for fiscal year 2023.Prior to Enrome's engagement, there were no consultations regarding specific transactions, audit opinions, or financial reporting matters between the firm and Universe Pharmaceuticals. The company has provided YCM with the disclosure and requested their confirmation letter to the SEC.
Universe Pharmaceuticals announced the appointment of Enrome LLP as its new independent registered public accounting firm effective October 8, 2024, replacing YCM CPA INC. The change was approved by the company's audit committee after careful consideration and evaluation.The company emphasized that the auditor change was not due to any disagreements on accounting principles, financial statement disclosure, or auditing procedures. YCM's audit reports for fiscal years 2022 and 2023 contained no adverse opinions or modifications. The only notable issue was previously reported material weaknesses under Item 15 of the company's annual report for fiscal year 2023.Prior to Enrome's engagement, there were no consultations regarding specific transactions, audit opinions, or financial reporting matters between the firm and Universe Pharmaceuticals. The company has provided YCM with the disclosure and requested their confirmation letter to the SEC.
大自然藥業宣佈任命Enrome LLP爲其新的獨立註冊公共會計師事務所,自2024年10月8日起生效,取代YCm CPA INC。該變更經過公司的審計委員會仔細考慮和評估後獲得批准。公司強調,核數師變更並不是因爲在會計原則、財務報表披露或審計程序上存在任何分歧。YCM對於2022和2023財政年度的審計報告沒有不利意見或修改。唯一值得注意的問題是公司2023財政年度年報第15項中先前報告的重要缺陷。在Enrome被聘用之前,事務所與大自然藥業之間沒有關於具體交易、審計意見或財務報告事項的諮詢。公司已向YCm提供了披露,並要求他們向SEC確認他們的確認函。
大自然藥業宣佈任命Enrome LLP爲其新的獨立註冊公共會計師事務所,自2024年10月8日起生效,取代YCm CPA INC。該變更經過公司的審計委員會仔細考慮和評估後獲得批准。公司強調,核數師變更並不是因爲在會計原則、財務報表披露或審計程序上存在任何分歧。YCM對於2022和2023財政年度的審計報告沒有不利意見或修改。唯一值得注意的問題是公司2023財政年度年報第15項中先前報告的重要缺陷。在Enrome被聘用之前,事務所與大自然藥業之間沒有關於具體交易、審計意見或財務報告事項的諮詢。公司已向YCm提供了披露,並要求他們向SEC確認他們的確認函。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息